-
An updated meta-analysis of birth defects in infants with first trimester efavirenz exposure was conducted and included published literature up until July 2011.
-
-
Rivaroxaban (Xarelto), Janssen Pharmaceutical's once-a-day oral Xa inhibitor, has been approved for reducing the risk of stroke in patients with atrial fibrillation.
-
The importation of measles into the U.S. was discussed in these pages earlier this year.
-
Beginning in November 2010, players from several NBA teams were reported as suffering from the "stomach flu". An investigation was launched, querying 400 players and 378 staff members whether they had experienced nausea and/or vomiting sometime between November 10 and December 20.
-
The Advisory Committee on Immunization Practices (ACIP) of the CDC has updated their recommendations for immunization of health care providers (HCP) against communicable infectious diseases.
-
Seven types of common environmental surfacesrubber, glass, plastic, metal, sanded wood, cloth, and wheat crackerswere studied for recovery of ~200 viable virions of CMV strain AD 169 applied to 2 cm2 replicates on each surface. Virus was applied in 200 µL aliquots of phosphate-buffered saline (PBS).
-
A post hoc analysis was performed on patients with ESBL-EC bloodstream infections from 6 published prospective cohorts. Mortality and length of hospital stay in patients treated with BLBLI (amoxicillin-clavulanic acid or piperacillin-tazobactam) vs. carbapenem were compared in 2 cohorts: empirical therapy (ETC) and definitive therapy (DTC). Multivariate analysis was used to minimize confounding.
-
Authors from the helsinki university central hospital, a tertiary hospital in Finland, retrospectively reviewed patient records from 2005 to 2009 to define the causes of fever in returned travelers and to evaluate the diagnostic approach. The 462 records were selected through requests for malaria smears in the emergency department.
-
During November, 2011, I attended separate meetings dedicated to exploring the incidence of antimicrobial resistance in two areas of the developing world, India and Cambodia. The first, sponsored jointly by the American Society for Microbiology (ASM), the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), and the Indian Association of Medical Microbiologists (IAMM), was named the "International Workshop on Antimicrobial Resistance" and was held at the Haffkine Institute in Mumbai, India. Organized by Prof. Lance Peterson (ASM representative), Prof. Abhay Chowdhary (Director of Haffkine Institute), Prof. V. Ravi (President of the IAMM), and Prof. Guiseppe Cornaglia (President of ESCMID), the workshop brought together around 250 participants, principally from India, to discuss various aspects of antimicrobial resistance over a 2.5 day program.
